Other Open Access

Statistical Data Analysis Plan Efficacy Merck's HPV Vaccine (Studies 005, 007, 013, and 015) - Amendment 1 - August 2005

Lisa Lupinacci

2005_FDA_r_s_F11-7942 DAP-Efficacy-Studies-005-007-013-015

We obtained Gardasil® Data Analysis Plans (DAPs) from the FDA through Freedom of Information Act (FOIA) request. The above linked DAP introduced modifications in the study participants populations. Instead of “per protocol analysis” for the outcome CIN 2+ irrespective of HPV type, this DAP introduced a post-hoc subgroup analysis (subgroup of subjects negatives to 14 HPV types, called RMITT-2).

Files (2.8 MB)
Name Size
2005_FDA_r_s_F11-7942 DAP-Efficacy-Studies-005-007-013-015.pdf
md5:85c1aac9e132a3ed036be977268f7a88
2.8 MB Download
348
93
views
downloads
All versions This version
Views 348348
Downloads 9393
Data volume 261.3 MB261.3 MB
Unique views 325325
Unique downloads 8484

Share

Cite as